Welcome to our dedicated page for COMPASS Pathways Plc American Depository Shares news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on COMPASS Pathways Plc American Depository Shares stock.
Compass Pathways Plc (Nasdaq: CMPS) is a biotechnology company at the forefront of mental health innovation, dedicated to accelerating patient access to evidence-based therapies. Headquartered in London, UK, with offices in New York and San Francisco, Compass is pioneering a new model of psilocybin therapy, specifically targeting treatment-resistant depression (TRD). The company’s flagship product, a proprietary high-purity polymorphic crystalline formulation of synthetic psilocybin known as COMP360, is at the core of their therapeutic approach.
Compass Pathways has made significant strides in mental health care by combining psilocybin treatment with psychological support. This dual approach is designed to provide comprehensive care for patients unresponsive to standard treatments. COMP360 has been designated a 'Breakthrough Therapy' by the U.S. Food and Drug Administration (FDA) and also received the Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.
The company's research is supported by robust clinical trials. Compass has commenced a Phase 3 clinical program for COMP360, making it the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previous Phase 2b studies have shown that a single 25mg dose of COMP360 can significantly improve depressive symptoms with sustained effects over weeks. In addition to TRD, Compass is exploring the potential of COMP360 for treating post-traumatic stress disorder (PTSD) and anorexia nervosa through ongoing Phase 2 clinical trials.
Recent collaborations with leading healthcare institutions like Hackensack Meridian Health and Journey Clinical are aimed at understanding and optimizing the delivery models for COMP360, should it receive FDA approval. These partnerships also include exploration into therapist training and care reimbursement processes to ensure that the treatment can be integrated smoothly into existing healthcare systems.
Financially, Compass Pathways remains committed to transparency and regular updates to investors through various platforms including their website, social media, and investor relations channels. The company's vision is to create a world where mental well-being is within reach for all.
For the latest news and updates on Compass Pathways, visit www.compasspathways.com.
The global psychedelic drugs market witnessed growth, expanding from
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 9:30 am ET. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days afterward.
COMPASS focuses on accelerating patient access to innovative mental health solutions, particularly through its psilocybin therapy, COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (TRD). The company is conducting the largest-ever randomized, controlled, double-blind psilocybin therapy clinical program for TRD, following a successful phase 2b study that demonstrated significant improvements in depressive symptoms.
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, announced management participation in three significant events. These include:
- Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 pm ET
- Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:00 am ET
- Loop Capital Conference on March 14, 2023
Live webcasts will be available on their investors’ page, with replays for 30 days post-event. COMPASS focuses on providing innovative treatment options, notably their psilocybin therapy COMP360, which has been designated as a Breakthrough Therapy by the FDA and targets treatment-resistant depression.
FAQ
What is the current stock price of COMPASS Pathways Plc American Depository Shares (CMPS)?
What is the market cap of COMPASS Pathways Plc American Depository Shares (CMPS)?
What is Compass Pathways Plc?
What is COMP360?
What designations has COMP360 received?
What clinical trials are currently underway for COMP360?
Who are Compass Pathways' partners in mental health research?
Where is Compass Pathways headquartered?
How does Compass Pathways communicate with its investors?
What was the outcome of the Phase 2b study for COMP360?
What is the focus of Compass Pathways' latest research collaborations?
What is the mission of Compass Pathways?
